| Code | CSB-RA016331MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to MEDI-6570, targeting OLR1 (oxidized low-density lipoprotein receptor 1), also known as LOX-1. OLR1 is a cell surface scavenger receptor primarily expressed on endothelial cells, macrophages, and smooth muscle cells that mediates the uptake of oxidized LDL, a key contributor to atherosclerotic plaque formation. Upon binding oxidized LDL, OLR1 triggers inflammatory signaling cascades and endothelial dysfunction, playing a critical role in the pathogenesis of cardiovascular diseases including atherosclerosis, myocardial infarction, and stroke. Elevated OLR1 expression has also been implicated in metabolic disorders and certain cancers.
MEDI-6570 was developed as a therapeutic antibody candidate for cardiovascular indications, designed to block OLR1-mediated uptake of oxidized LDL and subsequent inflammatory responses. This biosimilar antibody serves as a valuable research tool for investigating OLR1 biology, studying oxidative stress pathways, exploring mechanisms of endothelial dysfunction, and evaluating potential therapeutic interventions in atherosclerosis and related cardiovascular conditions.
There are currently no reviews for this product.